As of 2025-06-02, the Intrinsic Value of Zhejiang Wecome Pharmaceutical Co Ltd (300878.SZ) is 2.18 CNY. This 300878.SZ valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 16.74 CNY, the upside of Zhejiang Wecome Pharmaceutical Co Ltd is -87.00%.
The range of the Intrinsic Value is 1.95 - 3.23 CNY
Based on its market price of 16.74 CNY and our intrinsic valuation, Zhejiang Wecome Pharmaceutical Co Ltd (300878.SZ) is overvalued by 87.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (4.04) - (0.69) | (1.50) | -108.9% |
| DCF (Growth 10y) | (1.78) - (7.04) | (3.06) | -118.3% |
| DCF (EBITDA 5y) | 1.95 - 3.23 | 2.18 | -87.0% |
| DCF (EBITDA 10y) | 0.03 - 0.09 | (1,234.50) | -123450.0% |
| Fair Value | 0.34 - 0.34 | 0.34 | -97.96% |
| P/E | 1.20 - 3.17 | 1.72 | -89.7% |
| EV/EBITDA | (9.30) - 7.04 | (1.95) | -111.7% |
| EPV | (12.40) - (17.20) | (14.80) | -188.4% |
| DDM - Stable | 0.61 - 2.36 | 1.48 | -91.1% |
| DDM - Multi | (5.16) - (9.84) | (6.36) | -138.0% |
| Market Cap (mil) | 2,423.78 |
| Beta | 1.36 |
| Outstanding shares (mil) | 144.79 |
| Enterprise Value (mil) | 2,463.34 |
| Market risk premium | 6.13% |
| Cost of Equity | 9.23% |
| Cost of Debt | 5.00% |
| WACC | 8.73% |